|
|
|
| Trends in incidence and mortality of thyroid cancer in cancer registration areas of Zhengzhou City from 2016 to 2021 |
| YAN Ruiping, LI Jianbin, AN Ge, GUO Xiangjiao, HUANG Ruoxuan, SONG Caijuan
|
| Zhengzhou Center for Disease Control and Prevention (Zhengzhou Institute of Public Health Supervision), Zhengzhou, Henan 450007, China |
|
|
|
|
Abstract Objective To investigate the trends in incidence and mortality of thyroid cancer in cancer registration areas of Zhengzhou City, Henan Province from 2016 to 2021, so as to provide evidence for developing targeted thyroid cancer prevention and treatment strategies. Methods Data on incidence and mortality of thyroid cancer with qualified registration quality were collected from cancer registration offices in Zhengzhou City. Crude incidence and crude mortality were calculated. The Chinese population-standardized incidence and world population-standardized incidence were calculated using the standard age structure from the Fifth National Population Census in 2 000 and Segi's world standard population structure, respectively. The average annual percentage change (AAPC) was used to analyze the trends in the incidence and mortality of thyroid cancer in Zhengzhou City from 2016 to 2021 across different gender, age, and urban-rural area. Results In 2021, the crude incidence, Chinese population-standardized incidence and world population-standardized incidence of thyroid cancer in Zhengzhou City were 42.55/105, 37.43/105, and 32.56/105, respectively. The crude mortality, Chinese population-standardized mortality and world population-standardized mortality were 1.07/105, 0.77/105, and 0.71/105, respectively. The Chinese population-standardized incidence and mortality in females were 2.64 times and 2.83 times those in males, respectively; those in urban areas were 2.25 times and 1.51 times those in rural areas, respectively. The crude incidence peaked in the group aged 55-<60 years at 92.52/105. From 2016 to 2021, the crude incidence and Chinese population-standardized incidence of thyroid cancer showed an upward trend (AAPC=21.797%, 22.725%, both P<0.05), with trends consistent across different genders and urban-rural areas with the total population. The crude incidence showed upward trends in the groups aged 20-<30 years, 30-<40 years, 40-<50 years, 50-<60 years, and 60-<70 years (AAPC=17.237%, 31.026%, 21.289%, 23.010%, and 11.752%, all P<0.05). From 2016 to 2021, the Chinese population-standardized mortality of thyroid cancer showed an upward trend (AAPC=15.196%, P<0.05), while the trend in crude mortality was not statistically significant (P>0.05). The crude mortality (AAPC=21.078%, 25.669%) and Chinese population-standardized mortality (AAPC=24.122%, 28.865%) in females and rural areas showed upward trends (all P<0.05). Conclusions From 2016 to 2021, the Chinese population-standardized incidence and mortality of thyroid cancer in cancer registration areas of Zhengzhou City showed an upward trend. Females, urban residents, and middle-aged and young populations are key groups for thyroid cancer prevention and control.
|
|
Received: 08 January 2026
Revised: 14 February 2026
Published: 23 March 2026
|
|
|
|
|
|
[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[2] TANG S D,ZI H,TAO H,et al.Secular trends of morbidity and mortality of thyroid cancer in five Asian countries from 1990 to 2019 and their predictions to 2035[J].Thorac Cancer,2023,14(36):3540-3548.
[3] HAN B F,ZHENG R S,ZENG H M,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[4] LI M M,DAL MASO L,PIZZATO M,et al.Thyroid cancer in adolescents and young adults:a population-based study in 185 countries worldwide[J].Lancet Diabetes Endocrinol,2026,14(2):112-122.
[5] 国家癌症中心.中国肿瘤登记工作指导手册(2016)[M].北京:人民卫生出版社,2016.
[6] 王少明,郑荣寿,韩冰峰,等.2022年中国人群恶性肿瘤发病与死亡年龄特征分析[J].中国肿瘤,2024,33(3):165-174.
[7] 伊可欣,郄然然,刘茵,等.2020年河南省恶性肿瘤发病与死亡特征及2010—2020年趋势分析[J].中国肿瘤,2025,34(11):829-837.
[8] 李佳佳,张小鹏,张俊青,等.2021年安徽省合肥市甲状腺癌流行特征及2013—2021年变化趋势分析[J].中国肿瘤,2025,34(3):188-194.
[9] 陈德芳,亓爱玲,王莹,等.2014—2023年济南市甲状腺癌流行特征及减寿分析[J].中国地方病防治,2025,40(2):104-108.
[10] DENARO N,ROMANÒ R,ALFIERI S,et al.The tumor microenvironment and the estrogen loop in thyroid cancer[J/OL].Cancers,2023,15(9)[2026-02-14].https://doi.org/10.3390/cancers15092458.
[11] LIU J,XU T M,MA L,et al.Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer[J/OL].Front Oncol,2021,11[2026-02-14].https://doi.org/10.3389/fonc.2021.593479.
[12] LAM D,DAVIES L,SAWKA A M.Women and thyroid cancer incidence:overdiagnosis versus biological risk[J].Curr Opin Endocrinol Diabetes Obes,2022,29(5):492-496.
[13] 项彩英,陈颖,汪德兵,等.2021年浙江省肿瘤登记地区甲状腺癌发病与死亡特征及2000—2021年变化趋势分析[J].中国肿瘤,2025,34(10):756-763.
[14] LI M M,ZHENG R S,DAL MASO L,et al.Mapping overdiagnosis of thyroid cancer in China[J].Lancet Diabetes Endocrinol,2021,9(6):330-332.
[15] 马靖茹,王智奕,孙美晨,等.中国超重肥胖流行状况与防控工作进展[J].中国预防医学杂志,2024,25(4):406-412.
[16] FIORE M,CRISTALDI A,OKATYEVA V,et al.Dietary habits and thyroid cancer risk:a hospital-based case-control study in Sicily (South Italy)[J/OL].Food Chem Toxicol,2020,146[2026-02-14].https://doi.org/10.1016/j.fct.2020.111778.
[17] SAENKO V,MITSUTAKE N.Radiation-related thyroid cancer[J].Endocr Rev,2024,45(1):1-29.
[18] 胡君,周锋,姜涌斌,等.中青年甲状腺结节患者发生甲状腺癌的工作、生活行为方式影响因素[J].环境与职业医学,2024,41(2):200-206.
[19] 陈芳,吴凯,徐明星,等.基于病例对照研究的甲状腺癌危险因素的Meta分析[J].中华地方病学杂志,2017,36(4):250-256.
[20] 中华人民共和国国家卫生健康委员会医政医管局.甲状腺癌诊疗指南(2022年版)[J].中国实用外科杂志,2022,42(12):1343-1357,1363.
[21] 阿迪拉·苏力旦,夏依达·乌斯满江,沙吾拉西·热加甫,等.2020年新疆肿瘤登记地区甲状腺癌流行特征及2016—2020年变化趋势分析[J].预防医学,2025,37(10):1020-1023,1028.
[22] 韩亚蓉,韩颖颖,蔡波,等.2013—2022年南通市甲状腺癌发病和死亡趋势分析[J].预防医学,2026,38(1):20-25. |
|
|
|
